A randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability and efficacy of six months' administration of AVANDIA (rosiglitazone maleate) in subjects with Relapsing-Remitting Multiple Sclerosis (MS)
Multiple Sclerosis, Relapsing-Remitting
Phase 2
A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013